Tag:
MBP8298
Latest Headlines
Latest Headlines
BioMS wins $10M milestone on pivotal trial progress
According to BioMS Medical, an independent monitoring board has recommended that a phase II/III study of dirucotide (MBP8298) in patients with secondary progressive MS should continue to completion.
